Crosstalk between ERK, AKT, and cell survival

Cancer Biology and Therapy

Volumn 15, Issue 3, 2014, Pages 245-246

  Dent, Paul ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

EGFR; Erlotinib; HNSCC; K RAS; MAPK ERK; NSCLC; PI 103; PI3K Akt

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; KRAS PROTEIN, HUMAN; MAPK1 PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

CELL SURVIVAL; ENZYME PHOSPHORYLATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; ANTAGONISTS AND INHIBITORS; HUMAN; METABOLISM;

HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84895451862     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.27541     Document Type: Review

References (7)

1. Jarvis WD, Fornari FA Jr., Auer KL, Freemerman AJ, Szabo E, Birrer MJ, Johnson CR, Barbour SE, Dent P, Grant S. Coordinate regulation of stress-and mitogen-activated protein kinases in the apoptotic actions of ceramide and sphingosine. Mol Pharmacol 1997; 52:935-47; PMID:9415703 (Pubitemid 28013711)
2. Niederst MJ, Engelman JA. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci Signal 2013; 6:re6; PMID:24065147; http://dx.doi.org/10.1126/scisignal.2004652
3. Gentry LR, Martin TD, Der CJ. Mechanisms of targeted therapy resistance take a de-TOR. Cancer Cell 2013; 24:284-6; PMID:24029226; http://dx.doi.org/10. 1016/j.ccr.2013.08.021
4. Reardon DB, Contessa JN, Mikkelsen RB, Valerie K, Amir C, Dent P, Schmidt-Ullrich RK. Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. Oncogene 1999; 18:4756-66; PMID:10467423; http://dx.doi.org/10.1038/sj.onc. 1202849 (Pubitemid 29417751)
5. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, Schmidt-Ullrich R. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogenactivated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999; 10:2493-506; PMID:10436007; http://dx.doi.org/10.1091/mbc.10.8.2493 (Pubitemid 29393505)
6. Toulany M, Minjgee M, Saki M, Holler M, Meier F, Eicheler W, Rodemann HP. ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition. Cancer Biol Ther 2014; Forthcoming; PMID:24351425; http://dx.doi.org/10.4161/cbt.27311
7. Zmajkovicova K, Jesenberger V, Catalanotti F, Baumgartner C, Reyes G, Baccarini M. MEK1 is required for PTEN membrane recruitment, AKT regulation, and the maintenance of peripheral tolerance. Mol Cell 2013; 50:43-55; PMID:23453810; http://dx.doi.org/10.1016/j.molcel.2013.01.037